Form 4 for XFOR X4 Pharmaceuticals, Inc

Accepted 2025-02-14 00:00:00 ET · period of report 2024-05-17 · accession 0001628280-25-005698 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
M	2025-02-14	2024-05-17+	XFOR	Baldry Mark	Chief Commercial Off	P - Purchase	$0.55	+35.0K	129.2K	+37%	+$19.3K
	2025-02-14	2025-02-12	XFOR	Baldry Mark	Chief Commercial Off	A - Grant	$0.00	+600.0K	729.2K	+464%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-05-17	P	A	21,646	$0.68	115,769	D	—	—	(F1) The Reporting Person purchased shares of common stock through the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan. Such purchases were inadvertently omitted from previous Form 4 filings and are now being reported.
2	Common	Common Stock	2024-11-15	P	A	13,404	$0.34	129,173	D	—	—	(F1) The Reporting Person purchased shares of common stock through the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan. Such purchases were inadvertently omitted from previous Form 4 filings and are now being reported.
3	Common	Common Stock	2025-02-12	A	A	600,000	$0.00	729,173	D	—	—	(F2) Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date.